Patents by Inventor Cécile Bonnafous

Cécile Bonnafous has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compound that specifically binds to KIR3DL2 for use in the treatment of peripheral T cell lymphoma
    Patent number: 12084498
    Abstract: The present invention relates to methods for the treatment, prevention and diagnosis of peripheral T cell lymphoma using compounds that specifically bind KIR3DL2. The invention also relates to use of antibodies that specifically bind KIR3DL2 in diagnostic and theranostic assays in the detection and treatment of peripheral T cell lymphoma.
    Type: Grant
    Filed: July 29, 2021
    Date of Patent: September 10, 2024
    Assignee: INNATE PHARMA
    Inventors: Cécile Bonnafous, Hélène Sicard, Renaud Buffet
  • Treatment of peripheral T cell lymphoma
    Patent number: 11999784
    Abstract: The present disclosure relates to methods for the treatment, prevention and diagnosis of peripheral T-cell lymphoma using compounds that specifically bind NKp46. Included in particular are compounds that bind NKp46 and deplete tumor cells that express NKp46 at their surface, and pharmaceutical compositions comprising the same. The disclosure also relates to the use of antibodies that specifically bind NKp46 in diagnostic and theranostic assays in the detection and treatment of peripheral T-cell lymphoma.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: June 4, 2024
    Assignee: INNATE PHARMA
    Inventors: Cécile Bonnafous, Hélène Sicard, Renaud Buffet, Mathieu Blery
  • Treatment of peripheral T cell lymphoma
    Patent number: 10344087
    Abstract: The present disclosure relates to methods for the treatment, prevention and diagnosis of peripheral T-cell lymphoma using compounds that specifically bind NKp46. Included in particular are compounds that bind NKp46 and deplete tumor cells that express NKp46 at their surface, and pharmaceutical compositions comprising the same. The disclosure also relates to the use of antibodies that specifically bind NKp46 in diagnostic and theranostic assays in the detection and treatment of peripheral T-cell lymphoma.
    Type: Grant
    Filed: February 13, 2014
    Date of Patent: July 9, 2019
    Assignee: INNATE PHARMA
    Inventors: Cécile Bonnafous, Hélène Sicard, Renaud Buffet, Mathieu Blery
  • TLR3 binding agents
    Patent number: 9944712
    Abstract: Disclosed herein are anti-TLR3 antibodies as well as methods of making and using them. The antibodies are particularly adapted to the treatment of autoimmune or inflammatory diseases using anti-TLR3 antibodies.
    Type: Grant
    Filed: May 30, 2013
    Date of Patent: April 17, 2018
    Assignee: Innate Pharma
    Inventors: Cécile Bonnafous, Laurent Gauthier, Yannis Morel, Carine Paturel, Ivan Perrot
  • TLR3 BINDING AGENTS
    Publication number: 20150140000
    Abstract: Disclosed herein are anti-TLR3 antibodies as well as methods of making and using them. The antibodies are particularly adapted to the treatment of autoimmune or inflammatory diseases using anti-TLR3 antibodies.
    Type: Application
    Filed: May 30, 2013
    Publication date: May 21, 2015
    Inventors: Cécile Bonnafous, Laurent Gauthier, Yannis Morel, Carine Paturel, Ivan Perrot
  • Methods of Using Phosphoantigen for the Treatment of Cancer
    Publication number: 20100029674
    Abstract: The present invention relates to compositions and methods useful for treating a cancer in mammals, including humans. The methods and compositions typically comprise use of a chemotherapeutic agent and a ?? T cell activator such that the composition is effective for treating a cancer. Preferably the composition enhances the effect of the ?? T cell activator and/or prevents or delays the escape of a tumor from control chemotherapy, particularly an anti-angiogenic chemotherapeutic agent.
    Type: Application
    Filed: November 16, 2007
    Publication date: February 4, 2010
    Applicant: INNATE PHARMA, S.A.
    Inventors: Jérôme Tiollier, Hélenè Scard, Cécile Bonnafous